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Abstract
Bone, one of the favored sites for tumor metastasis, is a dynamic organ undergoing formation and resorption. We found
bone metastasis with osteolytic lesion in the bone marrow of the femur by injecting BW5147 T-lymphoma cells into the tail
vein of AKR mice. To understand this bone destruction, we constructed a cDNA library from BW5147 with a cloning vector
that allowed in vitro synthesis of mRNAs, and then identified a particular cDNA clone by adding the conditioned medium
from Xenopus oocytes following injection of the mRNA synthesized in vitro to primary bone marrow heterogeneous cell
populations on hydroxyapatite thin films. By means of this method, we isolated a factor with 16% leucine residues, termed
neurochondrin, that induces hydroxyapatite resorptive activity in bone marrow cells resistant to bafilomycin A1, an inhibitor
of macrophage- and osteoclast-mediated resorption. Expression of the gene was localized to chondrocyte, osteoblast, and
osteocyte in the bone and to the hippocampus and Purkinje cell layer of cerebellum in the brain. This may provide insights
into the molecular mechanisms underlying bone resorption with potential implications for the activation of cells other than
macrophages and osteoclasts in bone marrow cells. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: Bone; Bone marrow cells ; Brain; Hydroxyapatite resorptive activity; Metastasis
Bone, composed of mineralized matrix in which
spindle- or plate-shaped crystals of hydroxyapatite
are incorporated [1], results from balanced ongoing
bone formation and resorption [2]. It is one of the
favored sites of tumor metastasis, indicating that the
bone microenvironment provides a fertile soil for the
growth of many tumors [3]. Bone metastases are
often accompanied by osteolysis, which causes severe
bone pain, fractures, nerve compression, and hyper-
calcemia [4]. The variability in metastatic patterns is
thought to be in£uenced by molecular and cellular
biologic characteristics of both the tumor cells and
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the tissues to which they metastasize. Although little
is known about osteolysis by tumor metastasis, bone
resorption-inducing factors may play an important
role in the formation of osteolytic metastatic foci in
the bone [5].
Fusion of nonmetastatic tumor cells with normal
host cells may give rise to hybrid cells with a highly
increased metastatic potential. Evidence supporting
this notion has been obtained in a number of systems
both in vitro and in vivo [6^8]. The in vivo generated
hybrids of mouse BW5147 T-lymphoma cells, which
are noninvasive and nonmetastatic, and normal host
T-lymphocytes were demonstrated to acquire meta-
static potential in syngeneic mice and to cause exten-
sive and widespread tumor growth in the liver,
spleen, kidney, and ovary [9,10]. As shown in Fig.
1A, we found bone metastasis with osteolytic lesion
in the bone marrow of the femur by injecting
BW5147 T-lymphoma cells into the tail vein of
AKR mice, in addition to the liver metastasis (data
not shown).
To understand the cellular mechanism of this bone
destruction, we used hydroxyapatite thin ¢lms with
primary bone marrow cell populations, which are
known to be resorbed by osteoclasts that create re-
sorption lacunae [11], and tried to isolate a clone
capable of activating bone marrow cells for resorbing
hydroxyapatite with conditioned medium from Xen-
opus oocytes into which the mRNA mixture synthe-
sized in vitro from BW5147 cells was injected. The
collection and culture of oocytes, as well as the in-
struments and techniques needed for injection, were
previously described [12]. From the source of plas-
mid DNA prepared from each individual pools of
the cDNA library, the mRNA was synthesized in
vitro with the mCAP capping kit (Stratagene) ac-
cording to the manufacturer’s protocol. In an experi-
ment, 50 nl of mRNA at 1 mg/ml was injected into
an oocyte. After 72 h, the conditioned medium was
harvested as the assay sample and stored at 4‡C until
assayed. Clones from each positive pool were subdi-
vided and screened until a single clone was obtained.
Fig. 1. Hydroxyapatite resorptive activity of neurochondrin. (A) Bone metastasis in the femora. AKR female mice were injected into
the tail vein with BW5147 cells in PBS (lower) or with PBS alone (upper). Mice were killed when moribund or after 4 weeks, and tis-
sues were ¢xed in 4% formalin for 3 days, followed by acidic demineralization in 5% trichloroacetic acid for 2 days, dehydration, and
embedding in para⁄n. All sections were cut at 4 Wm and stained with hematoxylin and eosin. The bone trabeculae of the femur were
thinned and decreased in number. Magni¢cation, U15. (B) Hydroxyapatite resorptive activity of neurochondrin. The neurochondrin
cDNA expression vector was introduced into COS-7 cells, and then the cell conditioned medium was harvested after 3 days of culture.
Primary bone marrow cells were cultured on the hydroxyapatite thin ¢lms in the presence of conditioned media described above for
1 week. Mock transfected COS-7 cells were treated in the same way. The results are expressed as the number of pits per well. Values
are the mean þ S.D. for four independent experiments. *P6 0.01. (C) Pits formed on the hydroxyapatite thin ¢lms. Arrows indicated
lacunae induced by the conditioned media from neurochondrin transfected (lower), or mock transfected (upper) COS-7 cells. Magni¢-
cation, U300.
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Fig. 2. Nucleotide and deduced amino acid sequences of mouse neurochondrin. Nucleotides are numbered in the left margin. Amino
acids are denoted by one-letter code, and the positions are indicated in the right margin. Open circles indicate the putative initiator
methionines. The 354 bp sequence is boxed. The putative leucine zipper motif is shown by dots and the stop codon is indicated by an
asterisk. A double underline indicates the polyadenylation signal sequence.
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Following our experimental design, a mixture of
cDNA clones comprising the responsible products
would be identi¢ed by counting the number of pits
formed on the hydroxyapatite thin ¢lm plate after
removal of primary bone marrow cells. We used a
hydroxyapatite thin ¢lm coated plate (Osteologic
MultiTest slide, Millennium Biologix Inc., Canada)
for the resorption assay [11]. Bone marrow cells
(6U105) were obtained from 6^12-week-old male
C3H/Hej mice (Clea Japan, Inc., Japan), by the
method as described [13], and plated on Osteologic
MultiTest slide with 20 Wl of the assay sample in 0.18
ml of K-MEM in the presence of 10% FBS and 1038
M 1,25(OH)2D3 (Sumitomo Pharmaceuticals, Ja-
pan). These plates were incubated at 37‡C for 7
days. Cultures were fed every 3 days by replacing
0.13 ml of old medium with fresh medium containing
20 Wl of the assay sample. Cells adherent to the well
surface were removed by 5 min treatment with 10%
sodium hypochlorite. The number of pits per well
was counted by re£ected light microscopy (Nikon,
Japan). The cDNA clone could subsequently be pu-
ri¢ed by stepwise fractionations of the cDNA mix-
ture on the basis of the in vitro mRNA synthesis and
hydroxyapatite resorptive assay. One positive pool
was identi¢ed and subdivided by sequential rounds
of selection, yielding a single plasmid clone.
The expression vector (pCAGGS [14]) including
the cloned DNA was then transfected into COS-7
cells, and the culture medium was subjected to
bone marrow cells plated on the hydroxyapatite
thin ¢lms. As shown in Fig. 1B,C, small resorption
pits were evident on the ¢lms with the conditioned
medium transfected with the cloned cDNA. Analysis
of the cDNA sequence revealed the existence of a
putative AUG initiation codon followed by an
open reading frame of 579 amino acids. Since the
predicted 5P-upstream sequences of the AUG codon
lacked the in-frame stop codon, indicating a poten-
tial extended open reading frame, we conducted
RACE-PCR to obtain clones containing more 5P se-
quences. The 5P-ends of the mouse neurochondrin
cDNA clones were isolated from the mouse testis
cDNA (Marathon-Ready cDNA, Clontech Labora-
Fig. 3. Expression of neurochondrin. (A) Northern blot analysis. Total RNA (20 Wg) of indicated mouse cell lines and a rat bone,
and poly(A) RNA of mouse various tissues were probed with a mouse neurochondrin cDNA (3065 bp fragment encompassing nu-
cleotides 614^3678) or with human L-actin cDNA. Both mouse and rat neurochondrin transcripts migrate as an approximately 4 kb
band. (B) Western blot analysis. A mouse brain extract and the culture medium prepared from BW5147 cells were electrophoresed on
a 10^25% gradient gel, and subjected to immunoblot analysis using an anti-neurochondrin polyclonal antibody produced by injecting
GST-neurochondrin (amino acids 151^729) fusion protein in chicken. Numbers on the left refer to molecular weight markers.
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tories Inc., Palo Alto, CA, USA) using 5P RACE-
PCR according to the manufacturer’s protocol.
PCR was performed with the following two speci¢c
primers for neurochondrin: C16-R9 (5P-AG-
CTCTGGGAGCAAGTTTCT-3P) and C16-R15 (5P-
ATGGCTACGGCTTTGACCAG-3P). The ampli¢ed
cDNA fragments were cloned into pGEM-T Easy
(Promega Corporation, Madison, WI, USA) and se-
quenced.
Comparison of the nucleotide sequences shows
Fig. 4. In situ hybridization analysis of neurochondrin in bone and brain tissues. The 465 bp DNA fragment encompassing nucleo-
tides 1079^1543 of mouse neurochondrin cDNA was prepared by polymerase chain reaction. The RNA probes to the mouse neuro-
chondrin cDNA were transcribed in vitro using either SP6 or T7 polymerase. In situ hybridization analysis was performed on cryostat
sections of the mouse bone and the rat brain. Adult rat brain was sectioned at 15 Wm thickness. The femora dissected from 20-day-
old mice ¢xed with periodate-lysine-paraformaldehyde were decalci¢ed for 3 weeks, processed for para⁄n embedding, and sectioned
at 7 Wm thickness. The brain section and the depara⁄nized sections of bone were hybridized and detected by anti-digoxigenin conjun-
gated with alkaline phosphatase. The femora dissected from 20-day-old mice (A^F) and the brain dissected from adult rat (G^K)
were hybridized with neurochondrin antisense (B^F, H, J, and K) and sense (A, G, and I) probes. Neurochondrin mRNA was de-
tected in chondrocytes (C), osteoblasts (D), osteocytes (E), ¢brocartilage cells of the tendon (F), hippocampus (H), and Purkinje cell
layer (J and K). Magni¢cation in A and B, U66; C^F, U190; G and H, U100; I and J, U75; K, U180.
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that the cDNAs fall into two classes, which di¡er by
the presence or absence of a 354 nucleotide segment
encompassing nucleotides 78^431 (Fig. 2). This dif-
ference, which was found in several independent
clones, probably results from an alternative splicing
event. The 5P extended open reading frames are pre-
ceded by each untranslated region with stop codons
in the same frame and composed of 729 (termed
mouse neurochondrin-1) and 712 (neurochondrin-2)
amino acids (DDBJ/GenBank/EMBL Data Bank
with accession number(s) AB017608 and
AB017609). The longer open reading frame shown
here had a strong similarity to rat norbin [15], but
the shorter one represented a novel isoform. The
amino acid composition of this protein includes
16% leucine. In a search for PROSITE motifs, a
leucine zipper motif between residues 565 and 586
at the C-terminal half was identi¢ed. However, an
essential prerequisite for the e¡ectiveness of a leucine
zipper is the formation of an K-helix of the respective
protein domain since only under these conditions do
the leucine residues, appearing with a periodicity of 7
in the motif, align properly to form the zipper struc-
ture [16]. Since glycine and proline residues are
present in the zipper motif of neurochondrin, no
continuous helix may be expected to form as both
residues break a helical structure [16].
Western blot analysis identi¢ed a single band of
about 80 kDa in the mouse brain extract (Fig. 3B,
lane 1), consistent with that of rat norbin. Interest-
ingly, a single shorter band, but not the longer one,
could be detected in the culture medium from
BW5147, an original cell line of the expression
cDNA library used, suggesting that the immunoreac-
tive protein is, at least in part, composed of a se-
creted form in this cell line (Fig. 3B, lane 2). North-
ern blot analysis of cells derived from bone tissues
and both adult and embryonic tissues revealed that
the accumulation of the transcripts (about 4 kb) is
restricted to rat bone, MC3T3 (osteoblastic cell line)
[17], ST2 (stromal cell line) [18], primary osteoblasts
of fetal op/op mouse calvaria [19] and to the brain,
as well as being found in BW5147 (Fig. 3A, lanes 1^
13). During mouse embryonic development, this
mRNA was gradually increased from day 7 and de-
tected at high levels on day 15 (Fig. 3A, lanes 14^17).
Detection of the mRNA transcripts by in situ hybrid-
ization in rat femora is shown in Fig. 4B^F. There
was high expression of the transcripts within prolif-
erating cartilage cells in the epiphysial plate, osteo-
cytes and osteoblasts in the trabecular bone. Signals
were also detected within the ¢brocartilage cells of
the tendon. In the rat brain, dense signals were ob-
served in the pyramidal cell and granule cell layers of
the hippocampus (Fig. 4H), in the Purkinje cell layer
of the cerebellum (Fig. 4J,K), and signals were
widely seen in the brain. A sense probe was used
as a negative control and it gave no signals (Fig.
4A,G,I). On the basis of its characteristic expression
pattern, we termed this cloned factor neurochondrin.
Bone resorption is thought to be a multistep proc-
ess involving migration of osteoclasts and/or osteo-
clast precursors to the bone surface, attachment of
the bone matrix, and subsequent degradation of the
underlying bone mineral by local acidi¢cation
through secretion of protons that dissolve hydroxy-
apatite crystal into resorption lacunae [20^22]. Ba¢lo-
mycin A1, an inhibitor of vacuolar H-ATPases (V-
ATPases), has been demonstrated to inhibit hydroxy-
apatite resorption mediated by osteoclasts and acti-
vated macrophages on the hydroxyapatite thin ¢lm
plate [23]. We examined the e¡ect of this inhibitor on
the pit formation in our assay system. As listed in
Table 1, ba¢lomycin A1 could signi¢cantly decrease
the number of pits in the mock conditioned medium,
showing the inhibition of endogenous hydroxyapatite
resorptive activity. The conditioned medium from
oocytes injected with the in vitro synthesized RNA
for GM-CSF, a positive control for macrophage ac-
tivation [24], promoted pit formation in comparison
with the mock experiment, and the inhibitor strongly
blocked this formation (Table 1). Interestingly, how-
ever, ba¢lomycin A1 was unable to inhibit the pit
formation induced by the conditioned medium
from oocytes injected with neurochondrin mRNA.
In addition, the tartrate-resistant acid phosphatase
(TRAP) assay, a cell-speci¢c marker for osteoclasts
and macrophages [25,26], indicated no enhanced
TRAP-positive cells in bone marrow populations
on the ceramic plate (data not shown). These results
suggest that the neurochondrin product induces the
hydroxyapatite resorptive activity in primary bone
marrow cells other than osteoclasts and macro-
phages.
The cellular mechanism responsible for local de-
struction of bone by tumor cells has been a contro-
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versial issue for many years, but it now appears
likely that osteoclasts are primarily responsible [27].
Healthy bone metabolism consists of osteoblast-
mediated bone formation coupled to osteoclastic
bone resorption, and one might generally accept
the hypothesis that activated osteoblasts secrete fac-
tors that directly or indirectly in£uence osteoclast
formation or function [28]. However, the precise
mechanism whereby osteoblasts mediate osteoclastic
bone destruction and bone resorption remains un-
clear. Given that neurochondrin produced by osteo-
blasts could activate a small fraction of cells respon-
sible for hydroxyapatite resorptive activity, except
for osteoclasts and macrophages, in primary bone
marrow cells used in our assay, our current study
may have an impact on how we identify contributory
cell populations to lytic bone diseases. In this respect,
a complete understanding of the function of neuro-
chondrin in the bone and the brain awaits the deter-
mination of its possible interacting partners and an
analysis of knockout mutants of neurochondrin.
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Table 1
E¡ects of ba¢lomycin A1 on hydroxyapatite resorptive activity
Sample Number of pits/well
Ba¢lomycin A1 (3) Ba¢lomycin A1 (+)
Mock 43 þ 8 5 þ 4
mGM-CSF 327 þ 49* 18 þ 3
Neurochondrin 193 þ 30* 154 þ 42
Neurochondrin and mouse GM-CSF mRNAs were injected
into Xenopus oocytes. After 7 days of incubation, the condi-
tioned media were harvested and analyzed for hydroxyapatite
resorptive activity in the presence or absence of ba¢lomycin A1
(1U1038 M). Values are the mean þ S.D. for four independent
experiments. *P6 0.01.
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